MBrace Therapeutics Unveils Lead ADC Trial Poster at 2024 ASCO Meeting

MBrace™ Therapeutics, Inc. ("MBrace"), a clinical-stage oncology firm dedicated to developing novel antibody-drug conjugates (ADCs) for solid tumor treatments, has announced its participation in the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled from May 31 to June 4, 2024, in Chicago, Illinois. During this event, MBrace will present a Trial in Progress (TIP) poster outlining their ongoing clinical study.

The focus of the poster will be the trial design, dosing regimen, and study protocol for MBRC-101, MBrace's lead investigational drug. This Phase 1/1b clinical trial (NCT06014658) is a first-in-human, multicenter, open-label study aimed at assessing the safety and effectiveness of MBRC-101 in patients suffering from advanced metastatic solid tumors that have become resistant to conventional treatments. Preliminary clinical data from this trial is expected to be available in the first half of 2025.

MBRC-101 is designed to selectively target the EphA5 receptor tyrosine kinase, a cell surface receptor that is highly expressed in various common cancers. By precisely targeting EphA5, MBRC-101 introduces a novel treatment approach for solid tumors, potentially offering new hope for patients with advanced cancers that have not responded to prior therapies.

"ADCs are a highly promising class of treatments that could provide better efficacy and tolerability," remarked Dr. Shiraj Sen, a medical oncologist and director of clinical research at NEXT Oncology – Dallas, who is also an investigator in the MBRC-101 study. Dr. Sen expressed optimism about the clinical progress of MBRC-101 and its potential benefits for patients with resistant forms of cancer.

The details of the ASCO 2024 presentation are as follows:
- Abstract Title: A multi-center, open-label phase 1/1b dose finding, safety, and pharmacokinetic study of MBRC-101, an Anth-EphA5 monomethyl auristatin (MMAE) antibody-drug conjugate, in advanced refractory solid tumors
- Presenter: Shiraj Sen, M.D., Ph.D., Medical Oncologist and Director of Clinical Research, NEXT Oncology – Dallas
- Session Type and Title: Poster Session – Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
- Session Date and Time: Saturday, June 1, 2024, 9:00 AM-12:00 PM CDT
- Poster Board #: 305b
- Abstract Number: TPS3161

MBRC-101 is an investigational ADC that specifically targets the EphA5 receptor tyrosine kinase, which is prevalent in several cancers such as breast, non-small cell lung (NSCLC), colorectal, gastric, and pancreatic cancers. The current MBRC-101-001 Phase 1/1b clinical trial is a dose-escalation and dose-expansion study involving patients with advanced metastatic solid tumors that have not responded to standard treatments. Further details about the trial and patient eligibility can be found on clinicaltrials.gov using the identifier NCT06014658.

MBrace Therapeutics is a clinical-stage pharmaceutical company focused on developing and commercializing innovative therapeutic agents for cancer patients. The company specializes in creating and validating novel ADCs through the use of SPARTA technology, a proprietary platform developed by its founders. Based in San Diego, CA, MBrace also conducts research at The Thomas O. Daniel Research Incubator in Summit, NJ.

MBrace continues to dedicate its efforts to bringing groundbreaking cancer treatments to patients, aiming to improve outcomes for those battling advanced and treatment-resistant cancers.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!